Moderna (MRNA +3.72%) is best known for its coronavirus vaccine, a product that generated more than $18 billion in revenue at its peak in 2022 and helped drive the stock higher during the early days of the pandemic. In the years that followed, demand for the vaccine declined, and earnings and stock performance also tumbled.But Moderna has been working to commercialize a broad range of infectious disease vaccines and advance oncology and rare disease candidates to spur a new phase of growth. And the company ...

Core Viewpoint - BioNTech is transitioning its focus towards oncology, with plans for 15 ongoing Phase 3 trials by the end of 2026, while also dealing with leadership changes due to the co-founders' new venture in next-generation mRNA technologies [1][4][6] Financial Performance - BioNTech reported a net loss of €1.14 billion ($1.33 billion) for 2025, but ended the year with €17.2 billion in cash and financial securities, indicating strong financial stability [3][6] - The company's stock price has fluctuated between $79.52 and $85.50, with a current market cap of $20.17 billion [2] Market Outlook - Morgan Stanley has set a price target of $128 for BioNTech, suggesting a potential increase of 52.58% from its current trading price of $83.89 [2][6] - Despite recent challenges, including a 21% drop in share price following the co-founders' departure announcement, the market remains optimistic about BioNTech's future growth potential in oncology and mRNA technology [2][5]

Core Viewpoint - BioNTech's stock has significantly declined following the announcement of the departure of co-founders Ugur Sahin and Ozlem Tureci, who plan to establish a new biotech company focused on mRNA technology [1] Company Transition - BioNTech is transitioning from a founder-led organization to a more industrialized global commercial oncology pharmaceutical company, which is seen as a critical juncture for the firm [1] - The company expects to launch multiple products by 2030, indicating a strategic shift in its operational focus [1] Financial Performance - BioNTech reported 2025 sales of 2.9 billion euros (approximately $3.33 billion), which exceeded expectations of $3.15 billion but is significantly lower than the $21.19 billion in sales reported in 2021 [1] - The stock plummeted over 19% to $81.76, marking its lowest point since August 2024, and the last time shares traded below $80 was in October 2020 [1] Future Prospects - The company anticipates a catalyst-rich 2026 with six late-stage data readouts across various drug categories, including immune system-modulating drugs and mRNA-based cancer treatments [1] - BioNTech is planning eight Phase 3 studies in collaboration with Bristol Myers Squibb for a drug targeting PD-L1 and VEGF to combat cancer [1] Leadership Concerns - The exit of the founders introduces significant uncertainty regarding whether new leadership can effectively execute the vision established by Sahin and Tureci [1] - Analysts express concerns about the ability of the new corporate leadership to maintain the innovative approach without the founders' insights on translational and clinical data [1]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing technologies to enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Summary of Moderna FY Conference Call (March 10, 2026) Company Overview - **Company**: Moderna (NasdaqGS:MRNA) - **Fiscal Year**: 2025 - **Key Highlights**: Strong execution across revenue and cost management, significant progress in product pipeline Financial Performance - **Revenue**: $1.9 billion for FY 2025, at the high end of guidance range [2] - **Cost Reduction**: Achieved over $2 billion in cost savings, exceeding the $1 billion target set for 2025 [3] - **Cash Balance**: Ended 2025 with a cash balance of $8.1 billion, including $600 million from a credit facility [3] Product Pipeline Developments - **COVID-19 Vaccines**: - Spikevax approved for pediatric use (ages 6 months to 5 years) [4] - Positive data from Phase 3 flu vaccine study, application filed in the U.S. and other territories [4] - **Cancer Pipeline**: - Intismeran in Phase 3 for adjuvant melanoma, fully enrolled renal cell carcinoma study [4] - **Rare Diseases**: Fully enrolled study in PA, expecting readout in 2026 [42] Revenue Growth Projections - **2026 Guidance**: Up to 10% revenue growth expected, driven by: - Continued penetration of Spikevax in the U.S. (24% market share) [5] - Strategic partnerships with the U.K., Canada, and Australia, expected to generate $1 billion in international revenue [11] - **U.S. Sales Decline**: Anticipated decline in U.S. sales from $1.2 billion to $1 billion (20% decline) [11] Combination Vaccine Opportunities - **Flu-COVID Combination**: - Positive CHMP opinion received, expected approval in Europe later in 2026, contributing to revenue in 2027 [12] - Anticipated strong demand from single-payer systems internationally due to cost-effectiveness [15] - **U.S. Market**: Ongoing discussions with the FDA regarding the combination vaccine filing [13] Oncology Market Potential - **Adjuvant Melanoma**: - Multibillion-dollar market opportunity, with a 50/50 partnership with Merck [22] - Positive Phase 2 data with a hazard ratio of 0.51, aiming for similar or better results in Phase 3 [20] - **Future Indications**: Potential synergism with Keytruda, ongoing studies in various cancer types [24] Operating Expenses and Break-even Analysis - **R&D Spending**: Anticipated decrease in cash costs to $3.5 billion-$3.7 billion by 2027, with a need for revenue in that range to break even [36] - **Growth Drivers**: Expected contributions from European market openings and new partnerships in Latin America and Asia-Pacific [37] Rare Disease Program - **Partnership with Recordati**: Expected milestone payments of $160 million and tiered royalties based on sales for the PA program [42] Conclusion - **Outlook**: Exciting year ahead with multiple product approvals and significant growth opportunities in both existing and new markets [43]

Financial Data and Key Metrics Changes - Total revenues for 2025 were EUR 2.9 billion, a slight increase from the prior year despite a decrease in COVID-19 vaccine revenues [27] - The company ended 2025 with EUR 17.2 billion in cash equivalents and security investments, positioning it strongly for future investments [28] - Adjusted non-IFRS net loss for 2025 was EUR 117 million [29] Business Line Data and Key Metrics Changes - The company maintained over 50% market share in major markets for its COVID vaccine, distributed in over 180 countries [6] - R&D expenses were approximately EUR 2.1 billion, slightly decreased from the prior year, aided by cost savings from active portfolio management [27] - The oncology programs advanced significantly, with over 4,000 patients enrolled across phase 2 and phase 3 studies [6][8] Market Data and Key Metrics Changes - The company anticipates lower COVID-19 vaccine revenues in 2026 due to declining demand in both the U.S. and European markets [30][31] - The U.S. market is expected to be particularly competitive, impacting revenue generation [30] Company Strategy and Development Direction - The company aims to transition to a tumor-centric clinical development program focused on high-incidence cancers, including lung and breast cancer [8] - A new independent company will be established to pursue next-generation mRNA innovations, with BioNTech retaining a minority stake [10][11] - The strategic focus will remain on late-stage oncology assets and combination therapies to maximize value [11][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its strategy and achieve significant clinical data output from 2026 to 2029 [33] - The transition to a new leadership structure is planned for the end of 2026, aligning with key milestones and data readouts [49][50] Other Important Information - The company has established a partnership with BMS to strengthen its oncology programs and de-risk its pumitamig initiatives [6][8] - The company is preparing for multiple late-stage data readouts in 2026, which are expected to inform pivotal trials [8][25] Q&A Session Summary Question: How will the mRNA therapeutics be split between BioNTech and the new company? - Management confirmed that all current mRNA capabilities will remain with BioNTech, while the new company will focus on next-generation innovations [37][40] Question: What is the profile for the new CEO search? - The supervisory board is looking for leaders with strong experience in late-stage development and commercial execution [44][46] Question: Why is the leadership transition happening now? - The transition is planned for the end of 2026, coinciding with significant data readouts and the need for industrialization [49][50] Question: Will BioNTech contribute capital to the new company? - BioNTech will not contribute cash but will transfer certain rights and mRNA technologies [54][55] Question: What are the expectations for COVID-19 vaccine revenues in 2026? - Lower revenues are anticipated due to market normalization and seasonal demand [95][96]

Financial Data and Key Metrics Changes - Total revenues for 2025 were EUR 2.9 billion, a slight increase from the prior year, despite a decrease in COVID-19 vaccine revenues [27] - R&D expenses were approximately EUR 2.1 billion, a slight decrease from the prior year, enabled by cost savings and positive effects from cost-sharing with BMS [27] - The company ended 2025 with EUR 17.2 billion in cash equivalents and security investments, positioning it strongly for future investments [28] - An adjusted non-IFRS net loss of EUR 117 million was reported for 2025 [29] Business Line Data and Key Metrics Changes - The company maintained over 50% market share in the COVID vaccine market, distributing its vaccine in over 180 countries [6] - Significant progress was made in oncology programs, with over 4,000 patients enrolled across phase II and phase III studies [6] - The company executed strategic deals, including acquiring Biotheus and CureVac, to strengthen its oncology pipeline [7] Market Data and Key Metrics Changes - The company anticipates lower COVID-19 vaccine revenues in 2026 compared to 2025, driven by declines in both European and U.S. markets [30] - The U.S. market is expected to be competitive and dynamic, impacting revenue generation [30] - In Germany, direct sales of COVID-19 vaccines will significantly affect the company's top line [31] Company Strategy and Development Direction - The company aims to become a multi-product company by 2030, focusing on oncology and personalized medicine [10] - Key priorities for 2026 include accelerating late-stage development of oncology assets, building momentum in combination-based approaches, and evolving to a tumor-centric clinical development program [8] - The company plans to leverage its diverse clinical assets for combination strategies to address multiple lines of treatment [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and disciplined resource allocation, focusing on late-stage programs [8] - The transition to a new independent company for next-generation mRNA innovations is expected to enhance BioNTech's strategic focus [10] - Management anticipates a sustained cadence of event-driven late-stage readouts from 2026 to 2030, with significant potential to improve patient outcomes [9] Other Important Information - The company will supplement its IFRS reporting with adjusted non-IFRS measures to provide better context for business performance [28] - A binding agreement for the new company is expected to be signed by the end of the first half of 2026 [11] Q&A Session Summary Question: How will the mRNA therapeutics be split between BioNTech and the new company? - Management confirmed that all current mRNA capabilities will remain with BioNTech, while the new company will focus on next-generation innovations [38][40] Question: What is the profile for the new CEO search? - The supervisory board is looking for leaders with strong experience in late-stage development and commercial execution [46] Question: Why is the management transition happening now? - The transition is planned for the end of 2026, aligning with key milestones and data readouts [49][50] Question: Will BioNTech contribute capital to the new company? - BioNTech's contribution will relate to certain rights and mRNA technologies, not cash [54] Question: What are the expectations for COVID-19 vaccine revenues in 2026? - Lower revenues are anticipated due to market normalization and seasonal demand [95]

Financial Data and Key Metrics Changes - Total revenues for 2025 were EUR 2.9 billion, a slight increase from the prior year despite a decrease in COVID-19 vaccine revenues [26] - The company ended 2025 with EUR 17.2 billion in cash equivalents and securities, positioning itself strongly for future investments [27] - Adjusted non-IFRS net loss for 2025 was EUR 117 million, reflecting the impact of various expenses [28] Business Line Data and Key Metrics Changes - The company maintained over 50% market share in the COVID vaccine market, distributing its vaccine in over 180 countries [5] - Revenue from the BMS collaboration contributed EUR 613 million, offsetting declines in COVID-19 vaccine revenues [26] - R&D expenses were approximately EUR 2.1 billion, slightly decreasing from the prior year due to cost savings and collaboration benefits [26] Market Data and Key Metrics Changes - The company anticipates lower COVID-19 vaccine revenues in 2026, particularly in the U.S. and Europe, as the market normalizes [30] - The U.S. market is expected to be competitive, leading to lower revenues, while Germany's direct sales will significantly impact overall top line [30][96] Company Strategy and Development Direction - The company aims to accelerate late-stage development of oncology assets and focus on combination-based approaches [6] - A new independent company will be established to pursue next-generation mRNA innovations, allowing BioNTech to sharpen its strategic focus on its late-stage pipeline [9][10] - The company plans to transition from a platform-centric to a tumor-centric clinical development program, targeting high-incidence cancers [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and disciplined resource allocation, focusing on late-stage programs [6][27] - The company expects a sustained cadence of late-stage readouts from 2026 to 2030, with multiple pivotal trials planned [8] - Management emphasized the importance of maintaining a strong balance sheet while advancing key programs [33] Other Important Information - The company is transitioning leadership, with Ugur Sahin and Özlem Türeci remaining through the transition period [44] - The company is preparing for potential launches in oncology, including endometrial cancer, while building commercial capabilities [44] Q&A Session Summary Question: How will the mRNA therapeutics be split between BioNTech and the new company? - Management confirmed that all current mRNA capabilities will remain with BioNTech, while the new company will focus on next-generation innovations [36][39] Question: What is the profile for the new CEO? - The supervisory board is looking for leaders with strong experience in late-stage development and commercial execution [42][44] Question: Why is the leadership transition happening now? - The transition is planned for the end of 2026, aligning with key milestones and data readouts [46][47] Question: Will BioNTech contribute capital to the new company? - BioNTech will not contribute cash but will provide certain rights and mRNA technologies [51][53] Question: What are the expectations for COVID-19 vaccine revenues in 2026? - Lower revenues are anticipated due to market normalization, particularly in the U.S. and Europe [30][96]

Core Insights - BioNTech, initially focused on cancer, gained prominence during the COVID-19 pandemic by partnering with Pfizer to develop the first COVID-19 vaccine, Comirnaty, which peaked in sales at nearly $38 billion in 2022 [3][4] - Following the decline in vaccine sales as the pandemic subsided, BioNTech is refocusing on cancer treatments, investing heavily in a pipeline that includes vaccines, bispecific antibodies, and cell therapies [5] - The company is set to have 15 Phase 3 trials in cancer by the end of the year and anticipates multiple late-stage data readouts across major cancer types [6] Company Transition - Co-founders Ugur Sahin and Özlem Türeci will leave BioNTech by the end of the year to establish a new startup focused on next-generation mRNA innovations, with BioNTech granting certain rights to its mRNA technology in exchange for a minority stake [6] - BioNTech will concentrate on advancing its late-stage cancer medicine portfolio and is in the process of searching for successors to ensure a smooth transition [6] - Further details regarding the partnership with the new startup will be provided once an official deal is signed, expected to be completed by the end of the first half of the year [6]

Core Insights - BioNTech reported strong execution and pipeline momentum in 2025, with significant advancements in its oncology pipeline and a commitment to becoming a multi-product company by 2030 [3][5]. Financial Performance - For the full year 2025, BioNTech generated revenues of €2,869.9 million, an increase from €2,751.1 million in 2024, while the fourth quarter revenues were €907.4 million, down from €1,190.0 million in the same period last year [4][12]. - The company reported a net loss of €1,136.1 million for 2025, compared to a net loss of €665.3 million in 2024, with a diluted loss per share of €4.70, compared to a loss of €2.77 in the previous year [12][14]. - Adjusted net loss for the fourth quarter was €79.5 million, down from a profit of €432.4 million in the same quarter of 2024 [13][15]. Research and Development - R&D expenses for 2025 were €2,104.9 million, a decrease from €2,254.2 million in 2024, attributed to cost savings and active portfolio management [7][8]. - The company plans to focus on late-stage development and commercial readiness in oncology, with adjusted R&D expenses expected to be between €2.2 billion and €2.5 billion in 2026 [19]. Pipeline and Clinical Trials - BioNTech is on track for a catalyst-rich year in 2026, with six late-stage data readouts expected across various therapeutic areas, including immunomodulators and mRNA cancer immunotherapies [5][27]. - The company is advancing its bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned in collaboration with Bristol Myers Squibb [5][27]. Corporate Developments - BioNTech co-founders are establishing an independent company focused on next-generation mRNA innovations, with a management transition expected by the end of 2026 [29]. - The company maintains a strong financial position with cash, cash equivalents, and security investments totaling €17.2 billion as of December 31, 2025 [16][17]. 2026 Financial Guidance - BioNTech anticipates total revenues for 2026 to be between €2.0 billion and €2.3 billion, with lower COVID-19 vaccine revenues expected compared to 2025 [18]. - Adjusted SG&A expenses for 2026 are projected to be between €700 million and €800 million [19].